Issue 3/2012

  • Are released GM mosquitos safe?

    In this issue:

    • Novartis poised to enter HCV market with Enanta compound
    • Norway to use sequencing data in the country’s healthcare system
    • Oxford Nanopore shakes up Next-Gen sequencing market
    • BIO-Europe Spring: Antibodies – Unlocking new markets
    • Spain leads EU project for iPSCs in cell replacement therapies
    • Bioton joins forces with Actavis to develop biosimilar insulins
    • European Commission presents 2020 roadmap to bioeconomy

Volume 2015

Volume 2014

Volume 2013

Volume 2012

© 2007-2016 BIOCOM

http://www.european-biotechnology-news.com/magazine/ebsin/2012/3/pos/1.html?sort=desc&cHash=f5f2e5fdbfbf799a701ac9c5e77ce04b

Kurszettel

Alle Kurse

TOP

  • EVOCUTIS (UK)0.08 GBP14.29%
  • SERODUS (N)2.60 NOK4.00%
  • SUMMIT (UK)4.03 GBP3.87%

FLOP

  • SWEDISH ORPHAN BIOVITRUM (S)12.45 USD-23.38%
  • BIOTIE THERAPEUTICS (FI)0.14 EUR-22.22%
  • DIAMYD MEDICAL -B- (S)4.30 SEK-12.24%

TOP

  • VERONA PHARMA (UK)3.35 GBP26.4%
  • IXICO (UK)34.00 GBP15.3%
  • WILEX (D)1.95 EUR14.7%

FLOP

  • BIONOR PHARMA (N)0.86 NOK-44.9%
  • PROTHENA PLC (IE)31.71 USD-41.1%
  • PLETHORA (UK)2.62 GBP-36.4%

TOP

  • KARO BIO (S)26.00 SEK3614.3%
  • CHRONTECH PHARMA (S)0.34 SEK3300.0%
  • NICOX (F)7.00 EUR253.5%

FLOP

  • NEUROVIVE PHARMACEUTICAL AB (S)8.70 SEK-85.7%
  • BIOTEST (D)13.24 EUR-85.6%
  • EVOCUTIS (UK)0.08 GBP-71.4%

No liability assumed, Date: 08.02.2016